Cisplatin-Based Combinations-Associated Vasculopathy - A DisproportionalityAnalysis of Real-World Pharmacovigilance Data
Overall, these increased vasculopathies related to the use of cisplatin-based combinations can be related to the increased pro-thrombotic state in these patients. The results of this study highlight the need for caution when using cisplatin-based chemotherapy and the importance of monitoring patients for thrombotic events and other vasculopathies. Patient-specific factors, such as the type and stage of cancer, should be considered when determining the best treatment option and managing the risk of vascular complications.
Authors
- Fang Wei (ORCID: https://orcid.org/0000-0001-5904-2801)
- Chitsimran Mann (ORCID: https://orcid.org/0000-0002-3025-0145)
- Krutarth K Pandya (ORCID: https://orcid.org/0009-0005-2315-3151)
- Brijesh Patel
Institutions
- West Virginia University (US)
- Adventist Health Bakersfield (US)
- West Virginia University Hospitals (US)
- Cleveland Hearing & Speech Center (US)
- Cleveland Research (United States) (US)
Publication Details
- Journal
- Current Drug Safety
- Published
- 2025-08-08
- DOI
- https://doi.org/10.2174/0115748863312388240829190436
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00